Patents by Inventor Ashley M. Vaughan

Ashley M. Vaughan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TARGETING PLASMODIUM MALE GAMETE PROTEIN TO BLOCK MALARIA PARASITE TRANSMISSION
    Publication number: 20230390372
    Abstract: The disclosure provides immunogenic peptides comprising at least a portion of a Plasmodium HAP2 paralog (“HAP2p”) protein, immunogenic compositions comprising or encoding the immunogenic peptides, antibodies binding the immunogenic peptides, and methods of preventing Plasmodium transmission incorporating the peptides, compositions, and/or antibodies. In some embodiments, the immunogenic peptide has a sequence comprising a sequence with at least 80% identity to a sequence of at least 10 continuous amino acids of SEQ ID NO:2, a Plasmodium HAP2 paralog (“HAP2p”) protein.
    Type: Application
    Filed: August 27, 2021
    Publication date: December 7, 2023
    Applicant: SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE
    Inventors: Sudhir Kumar, Stefan H.I. Kappe, Ashley M. Vaughan, David Noah Sather
  • Doubly attenuated late liver stage malaria parasites and related compositions and methods
    Patent number: 11529404
    Abstract: The disclosure relates to doubly attenuated malaria parasites that have had the functionality of LISP2 and PlasMei2 genes interrupted through genetic manipulation. The double attenuated malaria parasites disclosed herein are useful for methods and compositions for stimulating of vertebrate host immune systems because of the complete cessation of lifecycle progression in the late liver stage, while providing a comprehensive antigenic presentation representing wildtype liver stage parasites. The disclosure also relates to the additional blood stage and gametocyte antigens to compositions of genetically attenuated malaria parasites (GAPs) to enhance efficient immune stimulation and prevention of disease and transmission related to the presence of blood stage parasites.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: December 20, 2022
    Assignee: SEATTLE CHILDREN'S HOSPITAL
    Inventors: Ashley M. Vaughan, Stefan H. I. Kappe, Dorender A. Dankwa
  • DOUBLY ATTENUATED LATE LIVER STAGE MALARIA PARASITES AND RELATED COMPOSITIONS AND METHODS
    Publication number: 20210353731
    Abstract: The disclosure relates to doubly attenuated malaria parasites that have had the functionality of LISP2 and PlasMei2 genes interrupted through genetic manipulation. The double attenuated malaria parasites disclosed herein are useful for methods and compositions for stimulating of vertebrate host immune systems because of the complete cessation of lifecycle progression in the late liver stage, while providing a comprehensive antigenic presentation representing wildtype liver stage parasites. The disclosure also relates to the additional blood stage and gametocyte antigens to compositions of genetically attenuated malaria parasites (GAPs) to enhance efficient immune stimulation and prevention of disease and transmission related to the presence of blood stage parasites.
    Type: Application
    Filed: February 1, 2021
    Publication date: November 18, 2021
    Applicant: SEATTLE CHILDREN'S HOSPITAL DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE
    Inventors: Ashley M. Vaughan, Stefan H.I. Kappe, Dorender A. Dankwa
  • Doubly attenuated late liver stage malaria parasites and related compositions and methods
    Patent number: 10905753
    Abstract: The disclosure relates to doubly attenuated malaria parasites that have had the functionality of LISP 2 and PlasMei2 genes interrupted through genetic manipulation. The double attenuated malaria parasites disclosed herein are useful for methods and compositions for stimulating of vertebrate host immune systems because of the complete cessation of lifecycle progression in the late liver stage, while providing a comprehensive antigenic presentation representing wildtype liver stage parasites. The disclosure also relates to the additional blood stage and gametocyte antigens to compositions of genetically attenuated malaria parasites (GAPs) to enhance efficient immune stimulation and prevention of disease and transmission related to the presence of blood stage parasites.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: February 2, 2021
    Inventors: Ashley M. Vaughan, Stefan H. I. Kappe, Dorender A. Dankwa
  • DOUBLY ATTENUATED LATE LIVER STAGE MALARIA PARASITES AND RELATED COMPOSITIONS AND METHODS
    Publication number: 20190381159
    Abstract: The disclosure relates to doubly attenuated malaria parasites that have had the functionality of LISP 2 and PlasMei2 genes interrupted through genetic manipulation. The double attenuated malaria parasites disclosed herein are useful for methods and compositions for stimulating of vertebrate host immune systems because of the complete cessation of lifecycle progression in the late liver stage, while providing a comprehensive antigenic presentation representing wildtype liver stage parasites. The disclosure also relates to the additional blood stage and gametocyte antigens to compositions of genetically attenuated malaria parasites (GAPs) to enhance efficient immune stimulation and prevention of disease and transmission related to the presence of blood stage parasites.
    Type: Application
    Filed: January 24, 2018
    Publication date: December 19, 2019
    Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research Institute
    Inventors: Ashley M. Vaughan, Stefan H.I. Kappe, Dorender A. Dankwa